Overview Request Sample Pages Request Customization Download PDF
You are viewing: Mexico Preimplantation Genetic Testing Market analysis

The Mexico Preimplantation Genetic Testing Market was valued at $4 Million in 2025 and projected to reach to $6.3 Million by 2030, representing a compound annual growth rate of 9.6%. Mexico's Preimplantation Genetic Testing market is poised for steady growth as fertility clinics increasingly adopt advanced genetic screening technologies to meet rising patient expectations.

Mexico Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Mexico Preimplantation Genetic Testing Market Trends and Insights

  • Mexico's market growth is driven by increasing adoption of assisted reproductive technologies, rising awareness of genetic screening benefits among fertility clinics, and growing patient demand for advanced diagnostic solutions.
  • The expansion reflects Mexico's strengthening healthcare infrastructure and the rising prevalence of genetic disorders awareness among reproductive medicine practitioners. In Mexico, the PGT market benefits from a large population seeking fertility treatments and the country's position as a regional hub for reproductive medicine.
  • Mexico's market dynamics are shaped by regulatory developments, increasing investment in fertility clinics equipped with genetic testing capabilities, and partnerships between local healthcare providers and international diagnostic laboratories.
  • By 2030, Mexico is expected to capture a larger share of Latin American PGT demand as accessibility and affordability improve across the country's fertility centers..

Key Market Statistics

  • CAGR (2025-2030) 9.6% CAGR
  • Market Size, 2025 ~USD 4 Million
  • Forecast, 2030 ~USD 6.3 Million
  • Country Mexico

Mexico Preimplantation Genetic Testing Market Overview

Market Valuation :

Mexico's Preimplantation Genetic Testing market is valued at $4.0 million in 2025, with projections to reach $6.3 million by 2030, representing significant growth potential in Latin America's fertility sector.

Growth Trajectory :

The Mexican market is expanding at a CAGR of 9.6% through 2030, driven by increasing adoption of assisted reproductive technologies and growing awareness among fertility clinics about genetic screening benefits.

Key Market Drivers :

Rising patient demand for advanced diagnostic capabilities, coupled with improved access to fertility treatments and increasing healthcare investments in Mexico, are propelling market expansion across major metropolitan areas.

Regional Opportunity :

Mexico represents a strategic growth market within Latin America, with expanding middle-class populations seeking advanced reproductive healthcare solutions and fertility clinics investing in cutting-edge genetic testing technologies.

Mexico Preimplantation Genetic Testing Market Dynamics

  • The market benefits from growing awareness of genetic testing benefits, improved healthcare infrastructure in major cities, and increasing disposable incomes among Mexican families seeking assisted reproductive treatments.
  • Expansion is supported by partnerships between international fertility centers and local clinics, enhancing service accessibility. Looking ahead to 2030, Mexico's PGT market will likely experience accelerated adoption driven by regulatory improvements, reduced testing costs, and enhanced patient education initiatives.
  • The convergence of technological advancement, rising infertility rates, and growing acceptance of assisted reproduction creates a favorable environment for market expansion.
  • Strategic investments by fertility clinics and potential entry of international diagnostic providers will further strengthen Mexico's position as a key Latin American market for preimplantation genetic testing services..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Mexico's PGT market is valued at $4.0 million in 2025 and will reach $6.3 million by 2030, growing at 9.6% CAGR.
      • Mexico's fertility clinic expansion and rising genetic awareness are primary drivers of market growth through 2030.
      • Mexico serves as a regional reproductive medicine hub, attracting both domestic and cross-border patients seeking PGT services.
      • Mexico's market growth is supported by improving healthcare infrastructure and increasing partnerships with international diagnostic providers.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Mexico Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES1.071.151.241.351.481.631.8210
      FERTILITY CLINICS3.043.243.483.784.124.514.965.469.4
      HOSPITALS0.770.810.860.9311.091.181.298.4
      OTHER END USERS0.270.290.30.320.350.370.40.447.6
      TOTAL5.155.485.896.396.967.618.359.189.3

      Target Audience

      • Fertility Clinic Operators : Mexican fertility clinics need market intelligence to justify investments in PGT technology, benchmark against competitors, understand patient demand trends, and plan service expansion strategies in their regions.
      • Diagnostic Service Providers : Genetic testing companies and diagnostic laboratories require Mexico-specific market data to assess market entry viability, identify clinic partnerships, understand pricing dynamics, and forecast revenue potential.
      • Healthcare Investors : Private equity firms and healthcare investors evaluating opportunities in Mexico's reproductive medicine sector need market sizing, growth projections, and competitive analysis to support investment thesis development.
      • Medical Device Manufacturers : Equipment and technology providers serving fertility clinics require Mexico market data to identify demand for PGT-related devices, understand adoption rates, and develop localized go-to-market strategies.
      • Healthcare Consultants : Management consulting firms advising healthcare clients in Mexico need accurate market data, growth drivers, and competitive insights to develop strategic recommendations for reproductive healthcare expansion.

      Key Companies in the Mexico Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market Size & Growth Data : Access precise valuation of Mexico's PGT market at $4.0M (2025) and $6.3M (2030) with verified CAGR of 9.6%, enabling accurate financial forecasting and investment planning specific to the Mexican market.
      • Competitive Landscape Intelligence : Understand Mexico-specific market dynamics, key fertility clinic players, diagnostic service providers, and competitive positioning to identify partnership and expansion opportunities in this emerging Latin American market.
      • Growth Driver Analysis : Gain insights into Mexico-specific factors driving adoption including rising awareness among fertility clinics, increasing patient demand for advanced diagnostics, and expanding assisted reproductive technology infrastructure.
      • Strategic Market Entry : Develop informed market entry strategies for Mexico with localized data on healthcare infrastructure, regulatory environment, fertility clinic distribution, and patient demographics to optimize resource allocation.
      • Investment Decision Support : Make confident investment decisions in Mexico's reproductive healthcare sector with comprehensive market analysis, growth projections through 2030, and identification of high-potential segments and geographic regions.

      Frequently asked questions

      What is the current size of Mexico's Preimplantation Genetic Testing market?

      Mexico's PGT market is valued at $4.0 million in 2025 and is expected to grow to $6.3 million by 2030.

      What is the projected growth rate for Mexico's PGT market?

      Mexico's PGT market is projected to grow at a compound annual growth rate of 9.6% from 2025 to 2030.

      What factors are driving growth in Mexico's PGT market?

      Mexico's market growth is driven by increased adoption of assisted reproductive technologies, rising genetic awareness among fertility clinics, growing patient demand for diagnostic solutions, and expanding healthcare infrastructure.

      Why is Mexico important for the Latin American PGT market?

      Mexico serves as a regional hub for reproductive medicine, attracting domestic and cross-border patients, and benefits from a large population seeking fertility treatments and advanced genetic testing services.

      How is Mexico's PGT market expected to evolve by 2030?

      By 2030, Mexico's PGT market is expected to capture a larger share of Latin American demand through improved accessibility, affordability, and increased investment in fertility clinics equipped with genetic testing capabilities.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status